Clinical Trials Logo

Clinical Trial Summary

Sufentanil Target Controlled infusion (TCI, Gepts model) effects on Neuromonitoring during Total Intravenous Anesthesia (TIVA) with Propofol TCI (Eleveld model) has not been investigate yet. Authors aim to investigate its effect on Patient State index (PSi), the power spectrum EEG, the Analgesia Nociception Index (ANI) nad pupillometry values during maintenance durin TIVA-TCI with Propofol and Sufentanil.


Clinical Trial Description

Sufentanil Target Controlled infusion (TCI, Gepts model) effects on Neuromonitoring during Total Intravenous Anesthesia (TIVA) with Propofol TCI (Eleveld model) has not been investigate yet. Authors aim to investigate its effect on Patient State index (PSi), the power spectrum EEG, the Analgesia Nociception Index (ANI) nad pupillometry values during maintenance durin TIVA-TCI with Propofol and Sufentanil. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06388408
Study type Observational
Source University of Padova
Contact Federico Linassi, MD
Phone 0422322440
Email federico.linassi@gmail.com
Status Not yet recruiting
Phase
Start date May 5, 2024
Completion date September 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT03459404 - Sufentanil NanoTab PCA System/15 mcg for Acute Post-Operative Pain in Vertebral Surgery: A Preliminary Investigation
Recruiting NCT06374849 - Intraoperative Sufentanil and Chronic Postsurgical Pain in Non-major Scheduled Abdominal Surgery Phase 4
Completed NCT04067648 - Sufentanil on Anesthesia Introduction and Recovery Quality in Pediatric Adenotonsillectomy N/A
Recruiting NCT04137198 - Sufentanil Intranasal Phase 4
Completed NCT03901716 - Comparison of Sufentanil, Fentanyl and Remifentanil in Combination With Midazolam During Bronchoscopy Under Conscious Sedation Phase 4
Completed NCT04791059 - Low-dose S-ketamine and Dexmedetomidine in Combination With Opioids for Postoperative Analgesia Phase 4
Terminated NCT02152514 - RCT Comparing Analgesia Post-VATS With Epimorph VS Placebo Phase 4
Not yet recruiting NCT05809804 - Median Effective Dose of Esketamine Pretreatment to Prevent Sufentanil-induced Cough N/A